Cabozantinib: a novel agent with a dual mechanism of action for castration-resistant prostate carcinoma
Author:
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology
Link
http://link.springer.com/content/pdf/10.1007/s00280-013-2343-2.pdf
Reference27 articles.
1. Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63:11–30
2. Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev M et al (2011) EAU guidelines on prostate cancer. Part II. treatment of advanced, relapsing and castration resistant prostate cancer. Eur Urol 59:572–583
3. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN et al (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502–1512
4. Berthold DR, Pond GR, Roessner M, de Wit R, Eisenberger M, Tannock AI (2008) Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 study. Clin Cancer Res 14:2763–2767
5. De Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I et al (2010) Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomized open-label trial. Lancet 376:1147–1154
Cited by 11 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Recent advancements in the small-molecule drugs for hepatocellular carcinoma (HCC): Structure-activity relationships, pharmacological activities, and the clinical trials;Biomedicine & Pharmacotherapy;2024-10
2. Assessing patient burden and benefit: A decade of cabozantinib clinical trials;International Journal of Cancer;2023-12-18
3. Immunotherapy for Metastatic Prostate Cancer;Urologic Oncology;2022
4. Increased therapeutic effect on medullary thyroid cancer using a combination of radiation and tyrosine kinase inhibitors;PLOS ONE;2020-05-27
5. Cabozantinib: A Multitargeted Oral Tyrosine Kinase Inhibitor;Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy;2018-02-07
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3